Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report

作者：Gharwan Helen; Tomita Yusuke; Lee Min Jung; Thomas Anish; Berman Arlene; Giaccone Giuseppe; Trepel Jane; Rajan Arun^*

来源：Oncology Letters, 2015, 10(2): 1155-1158.

DOI：10.3892/ol.2015.3325

• thymoma
• proteinuria
• nephrotic syndrome
• minimal change disease
• T-cells

The most frequently described glomerulopathy in patients with thymoma is minimal change disease (MCD). The present study reports the case of a 63-year-old female with recurrent thymoma and poorly-controlled paraneoplastic MCD, who was enrolled on a phase I/II clinical trial (no. NCT01100944) and treated with the histone deacetylase inhibitor, belinostat, in combination with cisplatin, doxorubicin and cyclophosphamide. Treatment resulted in a complete radiological response, a dramatic reduction in proteinuria and changes in immune cell subset composition, consisting of a reduction in the number of T helper (Th) 1, Th2, Th17 and regulatory T cells. Changes in T-cell polarization were also observed with an increase in the Th1/Th2 ratio. To the best of our knowledge, the current study is the first to provide a detailed description of changes in immune cell subset composition in thymoma-associated MCD. Early administration of effective antitumor therapy should be considered in these cases, particularly when proteinuria is poorly controlled despite the use of steroids and other immunosuppressive therapies.

• 出版日期2015-8
• 单位NIH